To examine the effects of Cerebrolysin on the treatment of diabetic peripheral neuropathy, we first established a mouse model of type 2 diabetes mellitus by administering a high-glucose, high-fat diet and a single int...To examine the effects of Cerebrolysin on the treatment of diabetic peripheral neuropathy, we first established a mouse model of type 2 diabetes mellitus by administering a high-glucose, high-fat diet and a single intraperitoneal injection of streptozotocin. Mice defined as diabetic in this model were then treated with 1.80, 5.39 or 8.98 m L/kg of Cerebrolysin via intraperitoneal injections for 10 consecutive days. Our results demonstrated that the number, diameter and area of myelinated nerve fibers increased in the sciatic nerves of these mice after administration of Cerebrolysin. The results of several behavioral tests showed that Cerebrolysin dose-dependently increased the slope angle in the inclined plane test（indicating an improved ability to maintain body position）, prolonged tail-flick latency and foot-licking time（indicating enhanced sensitivity to thermal and chemical pain, respectively, and reduced pain thresholds）, and increased an index of sciatic nerve function in diabetic mice compared with those behavioral results in untreated diabetic mice. Taken together, the anatomical and functional results suggest that Cerebrolysin ameliorated peripheral neuropathy in a mouse model of type 2 diabetes mellitus.展开更多
目的观察施普善对急性脑梗死患者磁共振氢质子波谱(H magnetic resonance spectroscopy,MRS)及临床症状、体征改善的影响,评价施普善治疗急性脑梗死的疗效。方法选择发病24h内的急性脑梗死患者40例,随机分为施普善治疗组20例及对照组20...目的观察施普善对急性脑梗死患者磁共振氢质子波谱(H magnetic resonance spectroscopy,MRS)及临床症状、体征改善的影响,评价施普善治疗急性脑梗死的疗效。方法选择发病24h内的急性脑梗死患者40例,随机分为施普善治疗组20例及对照组20例。2组治疗前及治疗2周后行美国国立卫生研究院脑卒中量表评分(NIHSS评分),应用MRS在兴趣区上测量氮-乙酰天冬氨酸(NAA)与肌酸(Cr)比值(NAA/Cr)、胆碱复合物(Cho)与肌酸(Cr)比值(Cho/Cr)及乳酸(Lac)与肌酸(Cr)比值(Lac/Cr),并对治疗前后结果进行统计学分析。结果治疗2周后2组NIHSS评分较治疗前均有所降低,施普善治疗组较对照组下降明显(P<0.05),2组病人NAA/Cr较治疗前升高,但施普善治疗组较对照组升高明显(P<0.05),2组病人CHO/Cr及Lac/Cr均较治疗前降低,但施普善治疗组较对照组降低明显(P<0.05)。结论施普善是一种有效的治疗急性脑梗死的神经保护剂。展开更多
文摘To examine the effects of Cerebrolysin on the treatment of diabetic peripheral neuropathy, we first established a mouse model of type 2 diabetes mellitus by administering a high-glucose, high-fat diet and a single intraperitoneal injection of streptozotocin. Mice defined as diabetic in this model were then treated with 1.80, 5.39 or 8.98 m L/kg of Cerebrolysin via intraperitoneal injections for 10 consecutive days. Our results demonstrated that the number, diameter and area of myelinated nerve fibers increased in the sciatic nerves of these mice after administration of Cerebrolysin. The results of several behavioral tests showed that Cerebrolysin dose-dependently increased the slope angle in the inclined plane test（indicating an improved ability to maintain body position）, prolonged tail-flick latency and foot-licking time（indicating enhanced sensitivity to thermal and chemical pain, respectively, and reduced pain thresholds）, and increased an index of sciatic nerve function in diabetic mice compared with those behavioral results in untreated diabetic mice. Taken together, the anatomical and functional results suggest that Cerebrolysin ameliorated peripheral neuropathy in a mouse model of type 2 diabetes mellitus.
文摘目的观察施普善对急性脑梗死患者磁共振氢质子波谱(H magnetic resonance spectroscopy,MRS)及临床症状、体征改善的影响,评价施普善治疗急性脑梗死的疗效。方法选择发病24h内的急性脑梗死患者40例,随机分为施普善治疗组20例及对照组20例。2组治疗前及治疗2周后行美国国立卫生研究院脑卒中量表评分(NIHSS评分),应用MRS在兴趣区上测量氮-乙酰天冬氨酸(NAA)与肌酸(Cr)比值(NAA/Cr)、胆碱复合物(Cho)与肌酸(Cr)比值(Cho/Cr)及乳酸(Lac)与肌酸(Cr)比值(Lac/Cr),并对治疗前后结果进行统计学分析。结果治疗2周后2组NIHSS评分较治疗前均有所降低,施普善治疗组较对照组下降明显(P<0.05),2组病人NAA/Cr较治疗前升高,但施普善治疗组较对照组升高明显(P<0.05),2组病人CHO/Cr及Lac/Cr均较治疗前降低,但施普善治疗组较对照组降低明显(P<0.05)。结论施普善是一种有效的治疗急性脑梗死的神经保护剂。
